Conclusion not exl. Medicine discount agreement according to § 130a Abs. 8 SGB V via an Open-House model for the active substance Natalizumab (WHO ATC code: L04AG03)

The AOK PLUS - The health insurance fund for Saxony and Thuringia in Germany from Europe region has released this tender for Subject of this publication is the conclusion of non-exclusive discount agreements pursuant to § 130a(8) SGB V on medicines containing the active substance Natalizumab (WHO ATC code: L04AG03). The contract conclusion takes place within the so-called 'Open-House' model, meaning that a contract conclusion is open to all interested pharmaceutical companies within the participation period, provided they meet the participation requirements and accept them. This results in no individual contract negotiations taking place and no (supply) exclusivity being granted. It is noted that the delivery quantity is unknown, as it depends on demand, the development of the insured number, the prescribing behavior of doctors, and the dispensing and stock management practices of public pharmacies. Minimum delivery quantities are therefore not guaranteed. Interested pharmaceutical companies can download the participation documents via the project space of the German Procurement Portal (DTVP). First, an application for access to the project space is required. After successful activation by the contracting authority, the participation documents can be accessed. Absolute confidentiality must be maintained regarding the content of the participation documents, particularly the discount agreement and the discounts mentioned therein. Any complete or partial disclosure or making available of participation document contents to or for third parties requires prior written consent from the contracting authority. If participation is withdrawn, all documents must be immediately destroyed in accordance with data protection regulations. The documents to be submitted are derived from the documents 'Cover letter' and 'Explanation of contract terms' deposited in the project space. Communication, including the submission of participation documents, takes place electronically via the procurement portal DTVP; details thereof are to be found in the previously mentioned documents. Any discrepancies in the tender notice are due to technical reasons and do not constitute binding obligations. Participation applications can be submitted for the first time until November 4, 2026. All further submission deadlines are to be found in the attached document 'Submission deadlines' in the project space. If the submission deadline falls on a Saturday, Sunday, or nationwide public holiday, the next working day is substituted. Late submissions will be considered for the next submission deadline. The discount agreement expires, regardless of the contract signing date, no later than November 30, 2027. The contracting authority reserves the right to terminate the Open-House procedure prematurely, in particular in the case of exclusive discount agreements; in such cases, the already concluded discount agreements will terminate according to contractual provisions. According to the contracting authority's experience, exclusive discount agreements typically come into effect 8 to 12 months after the publication of the corresponding tender notice in the EU Official Journal supplement. with tender notice no. 673520-2026 published on 07 Oct 2026. The tender is due to expire on 30 Nov 2027. This tender is sourced from TED Europa and is eligible for suppliers interested in Pharmaceutical products. Interested bidders can obtain further information including complete bid documents or ways to participate by registering on Tender Impulse and referencing via Tender Impulse ID 15298439.